Key result
Single-access balloon aortic valvuloplasty is reviewed as a contemporary technique to temporarily alleviate symptoms and bridge frail patients with severe aortic stenosis to definitive therapy.
Why the study?
Treating an increasingly frail population with severe symptomatic AS renewed interest in BAV as a bridge to definitive valve replacement or other urgent therapy.
Provides an overview of contemporary technical improvements in single-access balloon aortic valvuloplasty as a bridge to definitive therapy for frail patients with severe aortic stenosis.
Single-access BAV simplifies palliation or bridging in high-risk AS; extends technical options but leaves open need for prospective outcome data.
Balloon aortic valvuloplasty (BAV) was originally devised as an alternative approach for treating aortic valve stenosis (AS) in patients who could not undergo aortic valve replacement (AVR)1. However, BAV only provided temporary clinical and haemodynamic improvement and its use was therefore limited to palliative therapy2. Transcatheter aortic valve implantation (TAVI) has revolutionised the treatment of symptomatic severe AS in elderly patients with an elevated operative risk3. Treating this increasingly frail population has renewed interest in a therapy which could temporarily alleviate symptoms in order to bridge patients to definitive valve replacement therapy or other urgent therapy.
No takes yet. Share an insight, caveat, or question.
Ooms et al. (2019) conducted a review in Aortic valve stenosis. Single-access balloon aortic valvuloplasty was evaluated. Single-access balloon aortic valvuloplasty is reviewed as a contemporary technique to temporarily alleviate symptoms and bridge frail patients with severe aortic stenosis to definitive therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: